In situ immunophenotype of Langerhans cell histiocytosis cells in 25 patients
| Patient number . | Age/sex . | Clinical stage . | Biopsy site . | Immunostaining (LCH cells) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Langerin . | CD14 . | CD68 . | CD40 . | CD80 . | CD86 . | CD83 . | ||||
| 7459 | 7 y/M | EG | Bone | ++ | ++ | ++ | ++ | + | ± | − |
| 3774 | 2 y/F | EG | Bone | ++ | ++ | ++ | ++ | + | ± | ± |
| 10391 | 3 y/M | EG | Bone | ++ | ++ | ++ | ++ | ± | ± | − |
| 9980 | 11 y/M | EG | Bone | ++ | ++ | ++ | ++ | ++ | ± | − |
| 10337 | 6 y/M | EG | Bone | ++ | ++ | ++ | ++ | ++ | ± | ± |
| 2558 | 8 y/M | EG | Bone | ++ | ++ | ++ | ++ | + | ± | ± |
| 7553 | 6 y/F | EG | Bone | ++ | ++ | ++ | ++ | + | − | − |
| 3389 | 10 y/M | EG | Bone | ++ | ++ | ++ | ++ | ++ | ++ | ± |
| 5259 | 3 y/M | EG | Bone | ++ | ++ | ++ | + | ++ | − | − |
| 4188 | 8 y/M | EG | Bone | ++ | ++ | ++ | ++ | nd | − | − |
| 5149 | 6 y/F | EG | Bone | ++ | ++ | ++ | ++ | + | − | − |
| 9387 | 8 y/F | EG | Bone | ++ | nd | nd | nd | nd | nd | nd |
| 6423 | 1 mo/M | Skin (HP) | Skin | ++ | ± | ++ | ++ | + | + | + |
| 3807 | 15 d/F | Skin (HP) | Skin | ++ | ± | + | ++ | ++ | + | ± |
| 5828 | 7 d/F | Skin (HP) | Skin | ++ | + | ++ | ++ | ++ | + | ± |
| 5464 | 3 d/M | Skin (HP) | Skin | ++ | nd | nd | nd | nd | nd | nd |
| 3771 | 4 mo/F | Skin | Skin | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| 7333 | 7 mo/F | Skin | Skin | ++ | + | ++ | ++ | ± | + | ± |
| 7089 | 1 mo/M | Skin | Skin | ++ | ± | ++ | ++ | − | nd | − |
| 4968 | 8 mo/M | Skin | Skin | ++ | ± | ++ | ++ | ++ | + | ± |
| 6193 | 1 y/M | MS | Skin | ++ | + | + | ++ | + | − | − |
| LN | ++ | + | + | ++ | ++ | ± | ± | |||
| 6146 | 1 y/M | MS | Skin | ++ | nd | nd | nd | nd | nd | nd |
| Bone | ++ | + | + | + | − | − | − | |||
| LN | ++ | + | + | ++ | + | + | + | |||
| 6277 | 3 mo/M | MS | Skin | ++ | nd | nd | nd | nd | nd | nd |
| LN | ++ | ++ | ++ | ++ | nd | ± | ± | |||
| 8718 | 2 mo/F | MS | Skin | ++ | + | ++ | ++ | + | ± | ± |
| 564 | 2 mo/F | MS | Skin | ++ | nd | nd | nd | nd | nd | nd |
| Patient number . | Age/sex . | Clinical stage . | Biopsy site . | Immunostaining (LCH cells) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Langerin . | CD14 . | CD68 . | CD40 . | CD80 . | CD86 . | CD83 . | ||||
| 7459 | 7 y/M | EG | Bone | ++ | ++ | ++ | ++ | + | ± | − |
| 3774 | 2 y/F | EG | Bone | ++ | ++ | ++ | ++ | + | ± | ± |
| 10391 | 3 y/M | EG | Bone | ++ | ++ | ++ | ++ | ± | ± | − |
| 9980 | 11 y/M | EG | Bone | ++ | ++ | ++ | ++ | ++ | ± | − |
| 10337 | 6 y/M | EG | Bone | ++ | ++ | ++ | ++ | ++ | ± | ± |
| 2558 | 8 y/M | EG | Bone | ++ | ++ | ++ | ++ | + | ± | ± |
| 7553 | 6 y/F | EG | Bone | ++ | ++ | ++ | ++ | + | − | − |
| 3389 | 10 y/M | EG | Bone | ++ | ++ | ++ | ++ | ++ | ++ | ± |
| 5259 | 3 y/M | EG | Bone | ++ | ++ | ++ | + | ++ | − | − |
| 4188 | 8 y/M | EG | Bone | ++ | ++ | ++ | ++ | nd | − | − |
| 5149 | 6 y/F | EG | Bone | ++ | ++ | ++ | ++ | + | − | − |
| 9387 | 8 y/F | EG | Bone | ++ | nd | nd | nd | nd | nd | nd |
| 6423 | 1 mo/M | Skin (HP) | Skin | ++ | ± | ++ | ++ | + | + | + |
| 3807 | 15 d/F | Skin (HP) | Skin | ++ | ± | + | ++ | ++ | + | ± |
| 5828 | 7 d/F | Skin (HP) | Skin | ++ | + | ++ | ++ | ++ | + | ± |
| 5464 | 3 d/M | Skin (HP) | Skin | ++ | nd | nd | nd | nd | nd | nd |
| 3771 | 4 mo/F | Skin | Skin | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| 7333 | 7 mo/F | Skin | Skin | ++ | + | ++ | ++ | ± | + | ± |
| 7089 | 1 mo/M | Skin | Skin | ++ | ± | ++ | ++ | − | nd | − |
| 4968 | 8 mo/M | Skin | Skin | ++ | ± | ++ | ++ | ++ | + | ± |
| 6193 | 1 y/M | MS | Skin | ++ | + | + | ++ | + | − | − |
| LN | ++ | + | + | ++ | ++ | ± | ± | |||
| 6146 | 1 y/M | MS | Skin | ++ | nd | nd | nd | nd | nd | nd |
| Bone | ++ | + | + | + | − | − | − | |||
| LN | ++ | + | + | ++ | + | + | + | |||
| 6277 | 3 mo/M | MS | Skin | ++ | nd | nd | nd | nd | nd | nd |
| LN | ++ | ++ | ++ | ++ | nd | ± | ± | |||
| 8718 | 2 mo/F | MS | Skin | ++ | + | ++ | ++ | + | ± | ± |
| 564 | 2 mo/F | MS | Skin | ++ | nd | nd | nd | nd | nd | nd |
LCH cells in biopsy samples were positive for CD1a in all 25 patients. Staining with Langerin, CD14, CD68, CD40, CD80, CD86, and CD83 was evaluated on serial sections.
LCH indicates Langerhans cell histiocytosis; EG, eosinophilic granuloma; HP, Hashimoto-Pritzker disease; MS, multisystem disease; LN, lymph node. Most (++) denotes positivity of most (more than 75%) of cells; numerous (+), 25% to 75%; rare (±), less than 25%; negative (−), less than 5%; nd, not available.